Program Announcement

I. GENERAL INFORMATION

This program announcement is being released before the receipt of Federal funds appropriated in a bill for this program; funding of proposals received in response to this program announcement is contingent on the receipt of these funds at the United States Army Medical Research and Materiel Command (USAMRMC).

A. Title of Award: Prostate Cancer Research Program (PCRP) Clinical Trial Award.

B. Program Name: Department of Defense (DOD) Fiscal Year 2006 (FY06) PCRP.

C. Funding Opportunity Number: W81XWH-06-PCRP-CTA.

D. Agency Name: USAMRMC, Office of the Congressionally Directed Medical Research Programs (CDMRP), 1077 Patchel Street, Fort Detrick, Maryland 21702-5024.

E. Agency Contact(s)

1. Questions related to the program announcement, proposal format, or required documentation: Applicants should submit questions as early as possible. Every effort will be made to answer questions within 5 working days.

   Phone: 301-619-7079
   Fax: 301-619-7792
   E-mail: cdmrp.pa@amedd.army.mil
   Mail: Commander
   US Army Medical Research and Materiel Command
   ATTN: MCMR-ZB-C (PC06-CTA)
   1077 Patchel Street (Building 1077)
   Fort Detrick, MD 21702-5024

2. Questions related to electronic submission: A help line for questions relating to proposal submission and the CDMRP eReceipt Online Proposal Submission System is available Monday through Friday from 8:00 a.m. to 5:00 p.m. Eastern time at 301-682-5507. Help also is available on the CDMRP website or by e-mail as follows:

   Website: https://cdmrp.org (User’s Guide located in upper right corner of the proposal submission website)
   E-mail: help@cdmrp.org

F. Anticipated Instrument Type(s): The USAMRMC executes its extramural research program predominantly through the award of grants and cooperative agreements. More information on these funding instruments may be obtained by request from:
G. Catalog of Federal Domestic Assistance (CFDA) Number 12.420: Military Medical Research and Development.

H. Website to Access Application Package: Proposals must be submitted at https://cdmrp.org. This website contains all the information, forms, documents, and links needed to apply. Applicants experiencing difficulty in downloading documents should contact the CDMRP as indicated in Subsection I.E.2.

I. Award/Regulatory Approval: The applicant may not use, employ, or subcontract for the use of any human subjects, human biological substances, cadavers, or laboratory animals until applicable regulatory documents are requested, reviewed, and approved by the USAMRMC.

II. FUNDING OPPORTUNITY DESCRIPTION

A. Program History: The Clinical Trial Award is one of the mechanisms of the Prostate Cancer Research Program (PCRP), which was established in FY97 to promote research directed toward eliminating prostate cancer. Appropriations for the PCRP from FY97 through FY05 totaled $650 million (M). The Clinical Trial Award was offered in FY01 and FY05 when 44 Clinical Trial Award proposals were received and 10 were funded. The FY06 appropriation is $80M.

B. Program Objectives: The overall goal of the FY06 PCRP is to find and fund innovative, high-impact research that seeks to (1) prevent prostate cancer, (2) detect prostate cancer in its earliest stages of development, (3) cure prostate cancer, and (4) improve the quality of life for individuals living with prostate cancer and for their families.

C. Award Mechanism Description: The intent of the Clinical Trial Award is to provide for the rapid execution of novel patient-oriented research in a Phase I, Phase I/II, or Phase II clinical trial that has the potential to have a significant impact on prostate cancer. Proposals should focus on new interventions (e.g., drugs, biologics, and devices). It is expected that the clinical trial will be initiated within 6 months of the award date. This award is intended to support both new and established scientists across a broad spectrum of disciplines. The FY06 Clinical Trial Award is open to all eligible applicants with clinical trials relevant to prostate cancer treatment, diagnosis, detection, or prevention.

Note that Investigational New Drug (IND) and Institutional Review Board (IRB) approvals should be in process or completed before submission of an application to this program. IND
approval must be received before an award can be made. If IND approval is not received by April 30, 2007, the Government reserves the right to not fund the award. Funding from this award mechanism cannot be used for preclinical research studies; however, funds may be used for contract production of a drug or biological under Good Manufacturing Practices (GMP). Clinical Trial Awards will support Phase I, Phase I/II, and Phase II clinical trials (separate discussions are provided below for each type of clinical trial). Applicants must clearly specify in their proposals which type of clinical trial, Phase I, Phase I/II, or Phase II, is being proposed. Each proposal should contain only one clinical trial. Clinical trials must begin within 6 months of the award date. Local IRB approvals should be in process or completed before submission of the proposal to the Clinical Trial Award mechanism.

1. **Phase I Clinical Trials:** These trials should focus on determining the safety, toxicity, tolerability, and pharmacokinetics/pharmacodynamics of new interventions, devices, or treatment schedules in humans. It is expected that this award will allow the recipient the opportunity to obtain the data and experience necessary to conduct a Phase II clinical trial, if appropriate. Applicants for Phase I trials must include a clear scientific rationale for the trial as well as adequate preclinical supplemental data to support the feasibility of his or her hypotheses and approaches. Applicants must include a detailed plan for completing the Phase I trial during the performance period of the award and a clear experimental and appropriately powered statistical plan to perform the clinical trial. Phase I applicants are encouraged to pursue correlative studies.

2. **Phase II Clinical Trials:** These trials should focus on defining the efficacy of new interventions or devices. Applicants for Phase II clinical trials must include Phase I or pilot clinical trial data, adequate preclinical supplemental data to support the feasibility of their hypotheses and approaches, and a detailed plan for completion of the Phase II clinical trial during the award. Applicants must include a clear experimental and appropriately powered statistical plan to perform the Phase II clinical trial. Applicants are encouraged to pursue correlative studies.

3. **Phase I/II Clinical Trials:** These are Phase II-linked Phase I (Phase I/II) clinical trials, which must address all applicable requirements detailed above under Phase I and Phase II.

If the trial is multi-institutional, applicants should include plans for communication and real-time data transfer between the collaborating institutions as well as how specimens and/or imaging products obtained during the study will be handled in the appropriate sections of the Clinical Protocol (see Subsection V.K). An intellectual and material property plan agreed upon by all participating institutions is also required for multi-institutional clinical trials as part of the Supporting Documentation (see Subsection V.L).

Please note that all DOD-funded research involving human subjects, human anatomical substances, and/or cadavers must be reviewed and approved by the USAMRMC Human Subjects Research Review Board (HSRRB) in addition to local IRBs.
The HSRRB has different requirements than local IRBs. The average time to obtain HSRRB approval is approximately 6 months. Therefore, it is strongly suggested that the applicant plan the budget and timeline accordingly.

Important aspects of the Clinical Trial Award are:

- The proposal must include a named study coordinator who will guide the clinical protocol through IRB, HSRRB, and other regulatory approval processes, coordinate activities from all sites participating in the trial, and coordinate participant accrual.
- IRB approvals should be in process or completed before submission of the proposal to the Clinical Trial Award mechanism.
- IND or Investigational Device Exemption (IDE) approvals should be in process or completed before submission of the proposal to the Clinical Trial Award mechanism. **IND approval must be received before an award can be made.**
- The clinical trial should have a potentially high impact.
- The clinical trial must have clearly defined and appropriate endpoints.
- The proposal must include a well-written clinical protocol.

### III. AWARD INFORMATION

Funding for a Clinical Trial Award can be requested for a maximum of $750,000 for direct costs over the performance period. The performance period can be requested for up to 3 years. Indirect costs should be added as appropriate. Proposals for projects requiring lower levels of funding may also be submitted. Direct costs can cover salary, expenses including research supplies, equipment, and travel to scientific/technical meetings. Funds also may be used for contract production of a drug or biological under good manufacturing practices (GMP). Applicants also should budget for travel to a pre-award meeting and protocol workshop at Fort Detrick, Maryland, and a reverse site visit in the Baltimore, Maryland-Washington, DC area during the performance period. At a minimum, it is expected that the applicant and Clinical Research Coordinator will attend the pre-award meeting, although up to three individuals may attend. Justification must be provided if additional personnel are included in the travel budget. In addition, funding of $1,800 per investigator must be requested for travel to a PCRP Awardees Meeting (tentatively scheduled for the fall of 2007).

The nature of the PCRP does not allow for renewal of grants or supplementation of existing grants.

*The CDMRP expects to allot approximately $3M of the $80M FY06 PCRP appropriation to fund approximately three Clinical Trial Awards, depending on the quality and number of proposals received.*
IV. ELIGIBILITY INFORMATION

A. Applicants: Investigators at all academic levels (or equivalent) are eligible to submit proposals.

All individuals, regardless of ethnicity, nationality, or citizenship status, may apply as long as they are employed by, or affiliated with, an eligible institution as defined in Subsection IV.B, “Institutions” below.

To protect the public interest, the Federal Government ensures the integrity of Federal programs by conducting business only with responsible recipients. The USAMRMC uses the Excluded Parties List System (EPLS) to exclude recipients ineligible to receive Federal awards. The EPLS is online at http://epls.arnet.gov. (Reference Department of Defense Grant and Agreement Regulations (DODGAR) 25.110.)

B. Institutions: Eligible institutions include for-profit, nonprofit, public, and private organizations, such as universities, colleges, hospitals, laboratories, and companies. The USAMRMC is especially interested in receiving applications from Historically Black Colleges and Universities/Minority Institutions (HBCU/MI).

A DOD goal is to allocate funds for the CDMRP peer reviewed research to fund proposals from HBCU/MI. This provision is based on guidance from Executive Orders.¹ Proposals are assigned HBCU/MI status when the submitting institution is so designated by the Department of Education on the date the program announcement is released. The most current Department of Education list is posted on the CDMRP website at http://cdmrp.army.mil/spp under “Minority Institutions.”

Local, state, and Federal Government agencies are eligible to the extent that proposals do not overlap with their fully funded intramural programs. Federal agencies are expected to explain how their proposals do not overlap with their intramural programs.

Proposals from Federal agencies must provide a plan delineating how all funds will be obligated by September 30, 2007, and how funds will be available to cover research costs over the entire award period. The plan must include the funding mechanism(s) that will be used to carry over funds between fiscal years, such as administrative agreements with foundations, non-Federal institutions, and universities.

C. Duplicate Submissions: Submission of the same research project to different FY06 PCRP award mechanisms or to other CDMRP programs is discouraged. The Government reserves the right to reject duplicative proposals.

¹Executive Orders 12876, 12900, and 13021
V. PROPOSAL PREPARATION AND SUBMISSION INFORMATION

A. Proposal Components Summary: This subsection is a summary of submission requirements. Details, URLs, and other links are provided in the appropriate subsections of this program announcement. Proposals will be evaluated according to peer and programmatic review criteria in Section VI.

1. Applicant Responsibility: The applicant is responsible for entering and/or uploading the following information into the CDMRP eReceipt Online Proposal Submission System at https://cdmrp.org:

<table>
<thead>
<tr>
<th>Item</th>
<th>Tab</th>
<th>Format</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Letter of Intent (LOI)</td>
<td>Proposal Information</td>
<td>Typed</td>
<td>Copy the LOI into the data field. Click the “Save and Forward Letter of Intent” button to automatically create the LOI.</td>
</tr>
<tr>
<td>Proposal Information</td>
<td>Proposal Information</td>
<td>Typed</td>
<td>Enter the appropriate information in data fields.</td>
</tr>
<tr>
<td>Proposal Contacts</td>
<td>Proposal Contacts</td>
<td>Typed</td>
<td>Enter contact information for the applicant and the Contract Representative at the applicant’s institution.</td>
</tr>
<tr>
<td>Collaborators and Conflicts of Interest (COI)</td>
<td>Collaborator/COI</td>
<td>Typed</td>
<td>Enter information about collaborators and others outside the scope of the proposal who may have a COI in the review of this proposal.</td>
</tr>
<tr>
<td>Clinical Protocol</td>
<td>Required Files</td>
<td>PDF</td>
<td>Upload as a PDF file.</td>
</tr>
<tr>
<td>Supporting Documentation</td>
<td>Required Files</td>
<td>PDF</td>
<td>Upload as a PDF file.</td>
</tr>
<tr>
<td>Budget Information</td>
<td>Required Files</td>
<td>PDF</td>
<td>Upload as a PDF file.</td>
</tr>
<tr>
<td>Regulatory Documents</td>
<td>Required Files</td>
<td>PDF</td>
<td>Upload the Certificate of Environmental Compliance and the Principal Investigator Safety Program Assurance forms.</td>
</tr>
</tbody>
</table>
2. **Contract Representative Responsibility:** The Contract Representative (CR) or institutional official responsible for sponsored program administration (or equivalent) at the applicant’s institution is responsible for the following:

<table>
<thead>
<tr>
<th>Item</th>
<th>Tab</th>
<th>Format</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contract Representative’s Contact Information Profile</td>
<td>My Profile for the CR</td>
<td>Typed</td>
<td>Complete before electronic approval of all submission components.</td>
</tr>
<tr>
<td>USAMRAA*-Required Documents</td>
<td>My Profile for the CR</td>
<td>PDF</td>
<td>Upload the Rate Agreement, Certifications and Assurances for Assistance Agreements, and Representations for Assistance Agreements.</td>
</tr>
<tr>
<td>Approval</td>
<td>CR Approval</td>
<td>Click Approval Button</td>
<td>Click the button to approve the Proposal Information, Proposal Contacts, Collaborators and COI, Abstracts/Impact Statement/SOW, and Required Files before the submission deadline of 5:00 p.m. Eastern time, June 20, 2006.</td>
</tr>
</tbody>
</table>

*US Army Medical Research Acquisition Activity

B. **Proposal Format:** Proposals must be uploaded under the “Required Files” tab of the CDMRP eReceipt Online Proposal Submission System at [https://cdmrp.org](https://cdmrp.org). Applicants unfamiliar with the preparation of PDF files are encouraged to acquire and learn to use the appropriate software well in advance of the submission deadline. The instructions in this subsection must be followed carefully to prepare proposals for PDF submission.

The clinical protocol must be clear and legible and conform to the formatting guidelines described below. The font size, spacing, page size, and margins may differ between the word processing, PDF, and printed versions. These guidelines apply to the document properties of the electronic version of the PDF file(s) as viewed on the computer screen and submitted via the CDMRP eReceipt Online Proposal Submission System.

- **Font Size:** 12 point or larger.
- **Font Type:** Times New Roman is strongly recommended.
- **Spacing:** No more than six lines of type within a vertical inch (2.54 cm).
- **Page Size:** No larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).
- **Margins:** Must be at least 0.5 inch (1.27 cm) in all directions.
- **Print Area:** 7.5 inches x 10.0 inches (approximately 19.05 cm x 25.40 cm).
• **Color, High-Resolution, and Multimedia Objects**: Proposals may include color, high-resolution, or multimedia objects (e.g., MPEG, WAV, or AVI files) embedded in the PDF files; however, these objects must not exceed 15 seconds in length and a size of 10 MB. Since some reviewers work from black and white printed copies, applicants may wish to include text in the proposal directing the reviewer to the electronic file for parts of the proposal that may be difficult to interpret when printed in black and white. Photographs and illustrations must be submitted in JPEG format; bit map or TIFF formats are not allowed.

• **Internet URLs**: URLs directing reviewers to websites containing significant additional information about the proposed research are not allowed in the proposal or its components. Inclusion of such URLs may be perceived as an attempt to gain an unfair competitive advantage. Links to publications referenced in the proposal are allowed.

• **Language**: English.

Please note that headers should not be included, as the proposal log number will be electronically captured on each page of the proposal after receipt.

C. **Administrative Compliance Issues**: Compliance guidelines have been designed to ensure the presentation of all proposals in an organized and easy-to-follow manner. Peer reviewers expect to see a consistent, prescribed format for each proposal. *Failure to adhere to format requirements makes proposals difficult to read, may be perceived as an attempt to gain an unfair competitive advantage, and may result in proposal rejection.*

The following will result in administrative rejection of the entire proposal before it reaches peer review:

• Clinical protocol is missing.
• Detailed cost estimate is missing.
• Proposal is incomplete after the deadline.

For any other sections of a proposal with a defined page limit, pages exceeding the specified limit will be removed from the proposal and not forwarded for peer review.

Material submitted after the submission deadline, unless specifically requested by the Government, will not be forwarded for peer review.

The electronic PDF file uploaded in the CDMRP eReceipt Online Proposal Submission System is the official proposal submission file. After conversion of word processing documents to PDF files and before electronic submission, applicants should review their files to ensure that the proposal complies with the preparation guidelines outlined in this program announcement.

D. **Letter of Intent (LOI)**: An LOI (a brief description of the proposal) is entered in a data field under “My Proposals: Create New Proposal.” The LOI is saved when the “Save and Forward Letter of Intent” button is selected. The LOI may be modified under “Proposal
Information” at any time before the applicant submits this information by clicking “Finalize for CR Approval.” The LOI should be submitted by **May 23, 2006** at [https://cdmrp.org](https://cdmrp.org).

E. **Proposal Information:** Applicants are required to submit the Proposal Information as described in [https://cdmrp.org](https://cdmrp.org) before uploading the proposal, supporting documentation, and budget information.

- A **Title/Referral Page** for the proposal will be generated from the information uploaded in eReceipt and appended to the proposal electronically by the CDMRP eReceipt system.

F. **Proposal Contacts:** The Proposal Contacts *must* include the e-mail address of a Contract Representative authorized to negotiate on behalf of the applicant’s institution. The Proposal Contacts must be approved by the Contract Representative at the applicant’s institution.

G. **Collaborators and Conflicts of Interest (COI):** To avoid COI during the review process, list the names of all scientific participants in the proposal including collaborators, consultants, and subawardees. In addition, list the names of individuals outside the scope of this proposal who may have a COI in reviewing this proposal.

H. **Proposal Abstracts – 5,700-character limit including spaces (approximately one page), for each abstract:** Each abstract must include the applicant’s name and the title of the proposal. A structured technical abstract and a public (nontechnical) abstract are required. These abstracts are vitally important in both the peer review and programmatic review processes. Programmatic review is based on the Integration Panel’s review of these two abstracts as part of the peer review summary statements; therefore, it is of paramount importance that the applicant submits abstracts that describe the proposed work fully. Each abstract must be entered into the appropriate data field under the “Abstract/Impact/SOW” tab of the CDMRP eReceipt system.

Applicants can type the abstracts or “cut and paste” them from a word processing application into the respective data fields. *Spell out all Greek letters, other non-English letters, and symbols.*

Abstracts of all funded proposals will be posted on the CDMRP website at [http://cdmrp.army.mil](http://cdmrp.army.mil). Proprietary or confidential information should *not* be included in either the technical or the public abstract.

1. **Technical Abstract:** Sample technical abstracts can be found at [https://cdmrp.org/samples.cfm](https://cdmrp.org/samples.cfm). The structured technical abstract must provide a clear and concise overview of the proposed work. Use the outline below when preparing the structured technical abstract.

   - **Background:** Present the ideas and reasoning behind the proposed work.
   - **Objective/Hypothesis:** State the objective/hypothesis to be tested. Provide evidence or rationale that supports the objective/hypothesis.
   - **Specific Aims:** State the specific aims of the study.
• Trial Design: Briefly describe the proposed clinical trial including the intervention, proposed patient sample size, accrual, and outcome measures. Specify whether the proposed trial is a Phase I or Phase II clinical trial.
• Endpoints: Briefly but clearly describe the endpoints of the trial.
• Impact: Provide a brief statement explaining the impact of the proposed work to program goals. Describe how the proposed project will have an impact on the treatment and/or management of prostate cancer.

2. Public Abstract: Sample public abstracts can be found at https://cdmrp.org/samples.cfm. The public abstract is intended to communicate the purpose and rationale of the study to a non-scientifically trained audience. The public abstract is an important component of the proposal review process because consumer advocates, who are part of the review and funding decision process, use this abstract as a part of their review.

• Describe the clinical objective and rationale for the proposal in a manner readily understood by non-scientists.
  o Do not duplicate the technical abstract.
• Describe the ultimate applicability of the clinical trial to prostate cancer research or patient care.
  o What types of patients will it help and how will it help them?
  o What are the potential clinical applications, benefits, and risks?
  o What is the projected time it may take to achieve a consumer-related outcome?

I. Impact Statement – 5,700-character limit including spaces (approximately one page):
The Impact Statement is captured in a data field under the “Abstract/Impact/SOW” tab in the CDMRP eReceipt system. Applicants can type the Impact Statement into the data field or “cut and paste” it from a word processing application.

State explicitly how the proposed work will have an impact on the prostate cancer research field. Describe the impact of this study on the concepts and methods that drive the field(s) and/or the impact on the treatment and/or management of prostate cancer. Explain the potential clinical applications, benefits, and risks. The Impact Statement, which will be available at both peer and programmatic reviews, is often cited by consumer advocates during the review and funding decision processes.

J. Statement of Work – 11,400-character limit including spaces (approximately two pages): The SOW is captured in a data field under the “Abstract/Impact/SOW” tab in the CDMRP eReceipt system. Applicants can type the SOW into the data field or “cut and paste” it from a word processing application.

The SOW is a concise restatement of the research proposal that outlines, step by step, how each major goal or objective of the proposed research/services will be accomplished during the period for which the USAMRMC will provide financial support. When a proposal requesting funding
as part of a larger study is submitted, the proposal’s SOW must include DOD-funded tasks only. Sample SOWs can be found at https://cdmrp.org/samples.cfm.

The SOW should:

- Describe the work to be accomplished as tasks (tasks may relate to specific aims);
- Identify the timeline and milestones for the work over the performance period for the proposed effort;
- Allow 4 to 6 months for regulatory review and approval processes for human use studies;
- If applicable, indicate the sample size (including tissue, anatomical, or biological substances), projected or required for each task;
- Identify methods; and
- Identify outcomes, products, and deliverables for each phase of the project.


The clinical protocol is uploaded as a single PDF file under the “Required Files” tab of the CDMRP eReceipt system.

When a proposal is submitted requesting funding for part of a larger study, the clinical protocol must include DOD-funded tasks only.

Required elements for submission of a clinical protocol are:

1. **Protocol Title:** The protocol title must be the same as the proposal title. Please note that each proposal should contain only one clinical trial (clinical protocol) with a distinct study design.

2. **Phase:** Designate the protocol as Phase I or II.

3. **Principal Investigator:** List the complete name, address, telephone and fax numbers, and e-mail address of the Principal Investigator.

NOTE: Research investigators must complete appropriate institutional training before conducting human subjects research. Documentation of the most recent ethics training must be submitted for investigators of all protocols in the Supporting Documentation section of the proposal (Subsection V.L). In addition, for all investigational drug and device protocols, documentation of successful completion of a course in the conduct of clinical research in accordance with Good Clinical Practices (GCP) must be submitted for all investigators. The most recent ethics training and GCP course must be successfully completed within 1 year of the planned initiation of the protocol.

4. **Roles and Responsibilities of Study Personnel:** List the names of all personnel who will have significant involvement in the research study; include their practice license (e.g.,
M.D. or R.N.), highest degree(s), job title, and employing institution. Briefly describe the
duties of all study personnel to include each of the persons listed as investigators, research
staff, consultants, and the Medical Monitor. Describe their roles in the research effort (e.g.,
Research Coordinator, 80%, recruit and consent subjects, maintain study records, administer
study drug, take and record vital signs, enter data into computer database). Include a named
study coordinator who will be charged with guiding the protocol through the IRB, HSRRB,
and other regulatory approval processes, coordinating activities from all sites participating in
the trial, and coordinating participant accrual. In addition, include the name of the Medical
Monitor with his or her current curriculum vitae for Greater Than Minimal Risk Studies.
Duties of the Medical Monitor, as defined in HSRRB Clause 8.02
http://cdmrp.army.mil/funding/pdf/HSAppendix19Feb02.pdf are as follows:

“A Medical Monitor must be assigned to Greater Than Minimal Risk protocols. The
name and curriculum vitae of the Medical Monitor, who is someone other than the PI
[Principal Investigator], must be provided. This individual should be a qualified
physician who is not associated with the protocol, able to provide medical care to
research subjects for conditions that may arise during the conduct of the study, and able
to monitor subjects during the conduct of the study. In some studies it may be acceptable
to have a qualified health care provider other than a physician serve as Medical Monitor,
depending upon the type of risk that might occur in the study (e.g., a clinical
psychologist). The Medical Monitor is required to review all unanticipated problems
involving risk to volunteers or others, serious adverse events, and all volunteer deaths
associated with the protocol and to provide an unbiased written report of the event. At a
minimum the Medical Monitor should comment on the outcomes of the adverse event
and relationship of the event to the protocol or test article. The Medical Monitor should
also indicate whether he or she concurs with the details of the report provided by the PI.
Reports for events determined by either the investigator or Medical Monitor to be
possibly or definitely related to participation and reports of events resulting in death
should be promptly forwarded to the HSRRB.”

The Medical Monitor will forward reports to the USAMRMC, ATTN: MCMR-ZB-P, 504
Scott Street, Fort Detrick, Maryland 21702-5012.

5. Location of Study: List all centers, clinics, or laboratories where the study is to be
conducted. Include the name, degree(s), title, employing institution, and complete address of
the investigator(s) for each site.

6. Time Required to Complete the Study: State the month and year of expected start and
completion times.

7. Background: Suggested length – 10 pages. Describe the rationale for conducting the
study citing any relevant literature references. Include descriptions of any preliminary
studies and findings that led up to the development of the protocol and previous experience
most pertinent to the proposed study. In addition, Phase II clinical trial applicants must
provide Phase I or pilot clinical trial data. State the potential impact of the proposed clinical
trial on the treatment and/or management of prostate cancer. If the protocol was initiated
using other funding prior to obtaining funding managed by the USAMRMC, explain the history and evolution of the protocol and declare the source of prior funding. HSRRB approval is required prior to continuing enrollment using USAMRMC-managed funds.

8. Objectives: Suggested length – two pages. State the specific aims and the research strategy of the study. When a proposal is submitted requesting funding as part of a larger study, the aims and research strategy should be presented for DOD-funded tasks only. The applicant must address how the research plan will be affected if not all large study components receive funding (e.g., Can the DOD-funded research be completed as proposed if funding is not received for all components? What adjustments would be needed in the study design to meet such a contingency?).

9. Study Population

a. Target Population: Describe the target population (to whom the study findings will be generalized) and the nature, approximate number, and pertinent demographic characteristics of the accessible population at the study site (population from which the sample will be recruited/drawn).

b. Methods: Describe the methods that will be used to obtain a sample of subjects from the accessible population (e.g., convenience, simple random, stratified random) together with the inclusion and exclusion criteria (include age, gender, and ethnicity).

10. Protocol Design: Describe the type of study to be performed (prospective, randomized, controlled, etc.). Outline the proposed methodology in sufficient detail to show a clear course of action. Technological reliability and validity of procedures should be indicated. Minimum guidance for the plan should include:

a. Subject Identification: Describe the code system to be used to maintain the confidentiality of subjects.

b. Description of the Recruitment Process: Describe participant recruitment, including (1) participant availability; (2) inclusion and exclusion criteria; (3) methods for recruiting, retention, and follow-up; (4) data to support recruitment/retention estimates; (5) participant assignment to experimental groups and methods of randomization (if any); and (6) study endpoints. Provide copies of all recruitment and advertisement materials for review.

c. Description of the Informed Consent Process: Specifically describe the plan for the informed consent process by stating who will perform the informed consent interview and when the interview will take place relative to the subject beginning study participation and in relation to any stressful situation (e.g., being informed he or she has a malignant tumor) or in relation to the administration of any mind-altering substances such as tranquilizers, conscious sedation, or anesthesia. Address how privacy and time for decision making will be provided and whether the potential subject will be allowed to discuss the study with anyone before making a decision. Two copies of the informed
consent form should be completed so that the subject can get an original copy and a copy can be kept for the Principal Investigator’s study records. A third copy may be needed for the participant’s medical record; check with the participating site for specific study-site requirements.

d. **Plan for Addressing Human Subjects Protection Requirements:** Address any issues that may lead to concern for the welfare of human subjects and confidentiality as described by the HSRRB at [https://cdmrp.org/Program_Announcements_and_Forms](https://cdmrp.org/Program_Announcements_and_Forms) under “Regulatory Document Forms.”

e. **Subject Assignment:** Describe the randomization process or other procedures used for subject group assignments. Describe any potential biases in the protocol and how they will be addressed.

f. **Subject Screening Procedures:** List and describe any evaluations (e.g., laboratory procedures, history, and/or physical examination) that are required to determine eligibility/suitability for study participation. Please note that some screening procedures may need a separate consent or a two-stage consent process.

g. **Data Collection and Handling Procedures:** Describe all data collection procedures to be used in conducting the study (e.g., laboratory evaluations, specimens to be collected, schedule, and amounts). For studies using multiple measures or tests over time, it is helpful to display the data collection schedule in a spreadsheet or tabular format. Describe methods for the handling, distribution, analysis, storage (including where and whether special conditions are required), labeling, disposition, and security of specimens and/or imaging products (primary and secondary endpoints should be clearly defined and related to the power calculation). For multi-institutional trials, include a specimen handling and distribution plan agreed upon by all collaborating institutions.

h. **Clinical Assessments:** Provide a schedule of clinical, behavioral, laboratory, and physiological evaluations, and follow-up procedures. Provide any case report forms, data collection forms, questionnaires, rating scales, and/or interview guides that will be used in the study.

i. **Research Interventions:** Describe the research intervention or activity that the subject will experience. Provide sufficient detail in chronological order to enable a person not involved in the research to readily understand what the subject will experience.

j. **Data Management and Analysis:** Describe the data management and analysis plan, including the (1) overall approach to data management; (2) a plan for real-time data transfer; (3) a statistical plan that includes sample size calculations and methods to monitor quality and consistency of the intervention(s) and data collection; and (4) data security measures.
k. **Description of Protocol Drugs or Devices:** If the protocol uses an IND or IDE, provide the following information:

i. IND/IDE number and name of sponsor, if the study is in support of an application to the FDA.

ii. Complete names and composition of all medication(s), device(s), or placebo(s).

iii. Source of medications, devices, or placebos.

iv. Location of storage for study medications.

v. Dose range, schedule, and administration of test articles.

vi. Detailed description of washout period, if used.

vii. Duration of drug or device treatment.

viii. Concomitant medications allowed.

ix. Antidotes and treatments available.

x. Disposition of unused drug.

xi. The procedure by which the IND/IDE sponsor will monitor the protocol in accordance with 21 CFR 312.²

xii. The following items also need to be submitted:

   (1) A copy of the Investigator’s Brochure and/or device manual and associated case report/data collection forms. If the study involved the testing of an approved drug for a new indication, provide a copy of the package insert.

   (2) A signed Form FDA 1572 for IND/IDE Applications filed with the FDA, including the following information. Also, for non-FDA new drug protocols, the following information should be included in the protocol:

      (a) Name, address, and a statement of the qualifications for each investigator and the name of each sub-investigator working under the Principal Investigator.

      (b) Names and addresses of facilities to be used.

---

²Title 21 Code of Federal Regulations Section 312, which includes Investigational New Drug Application procedures and requirements. Additional information can be found at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfctfr/CFRSearch.cfm?CFRPart=312.
(c) Name and address of each IRB reviewing the protocol.

(3) For investigational devices, include the local IRB’s assessment of the risk (nonsignificant or significant) of the investigational device to be used in the study. If the device poses significant risk to research subjects, specify the IDE number obtained from the FDA, the name of the sponsor, and the procedure by which the sponsor will monitor the protocol in accordance with 21 CFR 812.3

l. Risks/Benefits Assessment

i. Describe risks (physical [including pain and discomfort, disfigurement, infection, injury, death], psychological, social, economic, legal, and privacy/confidentiality risks) associated with the research, measures to be taken to minimize and/or eliminate risks or to manage unpreventable risks, and special medical or nursing care that will be needed prior to, during, or following participation.

ii. Describe benefits of the research to the subject. If there will be no benefits to the subjects (other than knowing he or she has contributed to science), state this in the protocol and informed consent form.

iii. Payment or compensation for participation is not considered to be a benefit and must be addressed in a separate section.

m. Reporting of Serious or Unexpected Adverse Events

i. Serious or unexpected adverse events can occur in any and all types of studies, not just experimental interventions or clinical trials.

ii. Include a definition of what constitutes an adverse event in the proposed study.

(1) For IND or IDE research, refer to definitions as listed in 21 CFR 312.324 for assistance.

(2) All IND/IDE protocols must specify how the requirements described below regarding adverse events will be addressed.

“An adverse event temporally related to participation in the study should be documented whether or not considered to be related to the test article. This definition includes intercurrent illnesses and injuries and exacerbations of preexisting conditions. Include the following in all IND safety reports: Subject identification number and initials; associate investigator’s name and

---


name of medical treatment facility (MTF); subject’s date of birth, gender, and race/ethnicity; test article and dates of administration; signs/symptoms and severity; date of onset; date of resolution or death; relationship to the study drug; action taken; concomitant medication(s) including dose, route, and duration of treatment, and date of last dose.”

iii. Identify agencies or offices (including point of contact information) to be notified in the event of a serious and unexpected adverse event.

All protocols should contain the following language regarding the HSRRB reporting requirements for adverse events and unanticipated problems. (Note that unanticipated problems can occur in a study that does not require a research/clinical intervention.)

“Unanticipated problems involving risk to volunteers or others, serious adverse events related to participation in the study, and all volunteer deaths should be promptly reported by phone (301-619-2165), by e-mail (hsrrb@det.amedd.army.mil), or by facsimile (301-619-7803) to the U.S. Army Medical Research and Materiel Command’s Human Subjects Research Review Board. A complete written report should follow the initial notification. In addition to the methods above, the complete report can be sent to the U.S. Army Medical Research and Materiel Command, ATTN: MCMR-ZB-P, 504 Scott Street, Fort Detrick, Maryland 21702-5012.”


For protocols that have a Medical Monitor assigned (see Subsection V.K.4), the following language also should be included.

“The Medical Monitor is required to review all unanticipated problems involving risk to volunteers or others, serious adverse events, and all volunteer deaths associated with the protocol and provide an unbiased written report of the event. At a minimum, the Medical Monitor should comment on the outcomes of the event or problem and in the case of a serious adverse event or death comment on the relationship to participation in the study. The Medical Monitor also should indicate whether he or she concurs with the details of the report provided by the study investigator. Reports for events determined by either the investigator or Medical Monitor to be possibly or definitely related to participation and reports of events resulting in death should be promptly forwarded to the HSRRB.”

n. Disposition of Data: Describe where data will be stored, who will keep the data, how the data will be stored, and the length of time the data will be stored. Note that records of IND/IDE studies must be kept until 2 years after a New Drug Application is approved/issued or for 2 years after the IND/IDE is withdrawn. Records required for IDE studies should be retained for 2 years following the date that the investigation is
terminated or completed or the date that the records are no longer required for support of the pre-market approval application, whichever is sooner.

o. **Modification of the Protocol:** Describe the procedures to be followed if the protocol is to be modified, amended, or terminated before completion. Note that any modification of the protocol, informed consent form, and/or questionnaires, including a change of Principal Investigator, must be submitted to the local IRB for review and approval and then the HSRRB for second-level review and approval. Address this procedure even if no modification is anticipated.

p. **Departure from the Protocol:** Describe procedures and notifications to be made in the event of deviations from the approved protocol to include both the local IRB and the HSRRB.

q. **Study Organization and Management Plan:** Provide an organizational chart and a timetable for completion of the clinical trial and publication. Provide a plan for ensuring the standardization of procedures among staff and across sites (if applicable). Provide a plan for real-time communication among collaborating institutions (if applicable).

L. **Supporting Documentation:** Submit only material specifically requested in this program announcement. *This section is not intended for additional figures, tables, graphs, photographs, diagrams, chemical structures, pictures, pictorials, cartoons, or other information needed to judge the proposal.* Submitting material that was not requested may be construed as an attempt to gain a competitive advantage and such material will be removed; submitting such material may be grounds for administrative rejection of the proposal. Information on requirements for clinical documents can be found in the document titled “Research Involving Human Subjects and/or Anatomical Substances,” which can be found under “Regulatory Document Forms” at [https://cdmrp.org/Program_Announcements_and_Forms](https://cdmrp.org/Program_Announcements_and_Forms).

Supporting Documentation must be uploaded as a single PDF file under the “Required Files” tab of the CDMRP eReceipt system. All documents or letters that require signatures must be signed and incorporated into the supporting documentation file before it is submitted.

The first item in the Supporting Documentation file is the *Checklist/Table of Contents page.* The requested, allowable items in this section must be listed in the Checklist/Table of Contents; these include:

1. **Abbreviations:** Start section on a new page; one-page limit. Provide a list of all acronyms, abbreviations, and symbols used in the clinical protocol of the proposal.

2. **References:** Start section on a new page; no page limit. List all relevant references using a standard reference format that includes the full citation (i.e., author(s), year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).
3. **Biographical Sketches: Four-page limit per individual.** Include biographical sketches for all key personnel including collaborating investigators and support staff. These documents are a critical component of the review process. Incomplete or missing biographical sketches may result in lower proposal scores. The Biographical Sketch form may be used. Use of this form is not mandatory, but the information requested shall be presented in a similar format.

4. **Existing/Pending Support: Start section on a new page; no page limit.** List the titles, time commitments, supporting agencies, durations, and levels of funding for all existing and pending research projects involving the applicant and key personnel on a separate page. If no support exists, enter “None.” Proposals submitted under this program announcement should not duplicate other funded research projects.

5. **Facilities/Equipment Description: No page limit.** Describe the facilities available for performing the proposed research/services. Describe the institutional commitment, including any additional facilities or equipment proposed for purchase or available for use at no cost to the USAMRMC. Indicate whether Government-owned facilities or equipment are proposed for use.

6. **Letters of Support:** Provide letters of support from collaborating individuals or institutions.

7. **Publications and/or Patent Abstracts: Five-document limit.** Include up to five relevant publication reprints and/or patent abstracts. A patent abstract should provide a non-proprietary description of the patent application. If more than five publications are included in the submission, the extra items will not be peer reviewed.

8. **Clinical Documentation:** The following items must be included in this section.
   - Informed consent/assent forms.
   - Internal scientific and local IRB reviews for the clinical protocol.
   - Questionnaires.
   - Survey instruments.
   - Participant recruitment brochures.
   - Case report forms.
   - Investigator’s brochure for proposals with IND/IDEs.
   - Documentation that an IND/IDE has been submitted or approved.
   - A plan for study investigators to successfully complete institutional ethics training and a course in the conduct of clinical research in accordance with GCP within 1 year of initiation of the protocol.
   - Documentation that the participating institutions have an intellectual and material property plan and are willing to resolve intellectual and material property issues.
• A specimen handling and distribution plan agreed upon by all collaborating institutions for multi-institutional trials.

• Documentation of the availability of the substance or device to be used in the clinical trial. If the substance or device is to be provided from industrial sources, provide documentation of a cost-sharing plan.

M. Budget Information: Applicants must complete the Detailed Cost Estimate form and the Budget Justification form, and upload them as a single PDF file under the “Required Files” tab of the CDMRP eReceipt system. When a proposal requesting funding as part of a larger study is submitted, the proposal’s budget justification should include only DOD-funded tasks.

1. Funding Restrictions: Funding for a Clinical Trial Award can be requested for a maximum of $750,000 for direct costs over the performance period. The performance period can be requested for up to 3 years. Indirect costs should be added as appropriate. Proposals for projects requiring lower levels of funding may also be submitted. Direct costs can cover salary, expenses including research supplies, equipment, and travel to scientific/technical meetings. Funds also may be used for contract production of a drug or biological under GMP. Applicants also should budget for travel to a pre-award meeting and protocol workshop at Fort Detrick, Maryland, and a reverse site visit in the Baltimore, Maryland-Washington, DC area during the performance period. At a minimum, it is expected that the applicant and Clinical Research Coordinator will attend the pre-award meeting, although up to three individuals may attend. Justification must be provided if additional personnel are included in the travel budget. In addition, funding of $1,800 per investigator must be requested for travel to a PCRP Awardees Meeting (tentatively scheduled for the fall of 2007).

2. Detailed Cost Estimate Form and the Budget Justification Instructions: Budget is an important consideration in both peer review and programmatic review, and applicants are cautioned to use discretion in budget requests. Budgets also will be reviewed during award negotiations. Organizations must provide sufficient detail and budget justification so that the Government can determine the proposed costs to be allocable and reasonable for the proposed research. All costs must be entered in U.S. dollars.

The USAMRMC encourages in-kind contributions and cost-sharing for CDMRP-supported research. In-kind contributions may include support of services (e.g., laboratory services and salaries of personnel), real property and equipment, and/or supplies (e.g., drugs, devices, reagents) directly benefiting and specifically identifiable to the research project. It is expected that institutions will share the cost of equipment purchased for this research proposal. Please see full details under “Major Equipment” in Subsection V.M.2.c.

Costs proposed must conform to the following regulations and principles:


• **State, Local, and Tribal Governments**: OMB Circular A-87, Cost Principles for State, Local, and Indian Tribal Governments (http://www.whitehouse.gov/omb/grants/grants_circulars.html).

Follow the instructions below when providing the information requested in the Detailed Cost Estimate form.

a. **Personnel**

i. **Name**: Beginning with the applicant, list all participants who will be involved in the project during the initial budget period, whether or not salaries are requested. Include all collaborating investigators, research associates, individuals in training, and support staff. *The applicant must be identified as the Principal Investigator of the proposal.*

ii. **Role on Project**: Identify the role of each participant listed. Describe his or her specific functions in the Budget Justification section of the Detailed Cost Estimate form.

iii. **Type of Appointment (Months)**: List the number of months per year reflected in an individual’s contractual appointment with the applicant organization. The Government assumes that appointments at the applicant organization are full time for each individual. If an appointment is less than full time, e.g., 50%, note this with an asterisk (*) and provide a full explanation in the Budget Justification section of the Detailed Cost Estimate form. Individuals may have split appointments (e.g., for an academic period and a summer period). For each type of appointment, identify and enter the number of months on separate lines.

iv. **Annual Base Salary**: Enter the annual institutional base salary for each individual listed for the project.

v. **Percentage of Effort on Project**: The applicant’s qualifications and the amount of time that he or she and other professional personnel will devote to the research are important factors in selecting research proposals for funding. List the percentage of each appointment to be spent on this project for each key staff member. Include the percent effort of all unpaid collaborators and consultants.
Clinical studies must have a clinical coordinator who has sufficient time dedicated to the project to carry out the record keeping, coordination, and/or other administrative duties the project entails.

vi. Salaries Requested: Enter the salaries in whole U.S. dollars for each position for which funds are requested. Calculate the salary request by multiplying an individual’s institutional base salary by the percentage of effort on the project.

vii. Fringe Benefits: Fringe benefits for each position may be requested in accordance with institutional guidelines, provided the costs for all sponsors are treated consistently by the applicant’s organization. Provide documentation to support the fringe benefits.

viii. Totals: Calculate the totals for each position and enter these as subtotals in the columns indicated.

b. Consultant Costs: Provide the names and organizational affiliations of all consultants whether or not funds are requested.

c. Major Equipment: It is the policy of the DOD that all commercial and nonprofit recipients provide the equipment needed to support proposed research. In those rare cases where specific additional equipment is approved for commercial and nonprofit organizations, such approved cost elements shall be negotiated separately.

i. If the purchase of equipment for this research project is requested, it is expected that the applicant’s institution will share 50% of the cost.

ii. Permanent equipment is any article of nonexpendable tangible property having a useful life of 2 years or longer and an acquisition cost of $5,000 or more per unit.

iii. The basis for the cost of each item of permanent equipment included in the budget must be disclosed.

iv. Title of equipment or other tangible property purchased with Government funds may be vested in institutions of higher education or with nonprofit organizations whose primary purpose is the conduct of scientific research. Normally the title will vest in the recipient if vesting will facilitate scientific research performed by the institution or organization for the Government.

d. Materials, Supplies, and Consumables: A general description and estimated total cost of expendable equipment and supplies are required. Itemize supplies in separate categories (e.g., glassware, chemicals, radioisotopes). Categories in amounts less than $1,000 do not need to be itemized. If animals will be purchased, state the species, strain (if applicable), and the number of animals to be used. If human cell lines are to be purchased, state the source and the description.
e. **Travel Costs:** Costs for travel to scientific/technical meetings may not exceed $1,800 per year. Applicants also should budget for at most three individuals to travel to a pre-award meeting and protocol workshop at Fort Detrick, Maryland, and a reverse site visit in the Baltimore, Maryland-Washington, DC area during the performance period. Additional travel funds of $1,800 per investigator must be requested to attend a PCRP Awardees meeting (tentatively scheduled for the fall of 2007).

Travel costs associated with the execution of the proposed work should be entered in this section. If applicable, reasonable costs for travel between collaborating institutions should be included and are not subject to the yearly $1,800 limitation on travel to meetings. Justification for these travel costs should be provided. Travel outside the U.S. requires prior approval from the US Army Medical Research Acquisition Activity (USAMRAA).

f. **Research-Related Subject Costs:** Itemize costs of subject participation in the research study. These costs are strictly limited to expenses associated specifically with the proposed study. The USAMRMC will not provide funds for ongoing medical care costs not related to a subject’s participation in the research study.

g. **Other Direct Costs:** Itemize other anticipated direct costs such as publication and report costs, rental for computers and other equipment (provide hours and rates), and communication costs. Unusual or expensive items should be fully explained and justified. Estimate the costs of publishing and reporting research results, including direct charges for clerical preparation, illustrations, reprints, and distribution.

h. **Subaward Costs:** A description of services or materials to be awarded by subcontract or subgrant is required. For awards totaling $10,000 or more:

- Identify the type of award to be used (e.g., cost reimbursement, fixed price);
- Identify the proposed subcontractor or subgrantee, if known, and provide an explanation of why and how the subcontractor or subgrantee was selected or will be selected;
- Specify whether the award will be competitive and, if noncompetitive, provide a rationale to justify the absence of competition; and
- Provide the proposed acquisition price.

i. **Indirect Costs (overhead, general and administrative, and other):** The most recent rates, dates of negotiation, base(s), and periods to which the rates apply should be disclosed with a statement identifying whether the proposed rates are provisional or fixed.

j. **Total Costs for the Entire Proposed Period of Support (second page of the Detailed Cost Estimate form):** Enter the totals in each budget category for all additional years of support requested and itemize these totals in the Budget Justification section of the Detailed Cost Estimate form. Note with an asterisk (*) and explain any
significant increases or decreases from the initial year budget. All amounts should be in U.S. dollars. Directs costs, indirect costs, and the total cost for the entire proposed period of support should equal the amount entered in the “Required Files” tab at https://cdmrp.org.

3. **Budget Justification (third page of the Detailed Cost Estimate form):** Each item in the budget must be clearly justified in the Budget Justification section of the Detailed Cost Estimate form.

4. **Federal Agency Financial Requirement:** Proposals from Federal agencies *must* provide a plan delineating how all funds will be obligated by September 30, 2007, and how funds will be available to cover research costs over the entire award period. The plan must include the funding mechanism(s) that will be used to carry over funds between fiscal years, such as administrative agreements with foundations, non-Federal institutions, and universities.

   *Start the plan on a new page at the end of the Budget Information section.* The Federal Agency Financial Plan must be uploaded as part of the budget information before the submission deadline of 5:00 p.m. Eastern time, June 20, 2006.

N. **Regulatory Requirements:** Completed and signed copies of the [Certificate of Environmental Compliance](https://cdmrp.org) and [Principal Investigator Safety Program Assurance](https://cdmrp.org) form must be uploaded under the “Required Files” tab of the CDMRP eReceipt system as separate PDF files. In addition, regulatory documents pertaining to research involving human subjects and/or human anatomical substances or cadavers must be submitted within the Clinical Protocol and Supporting Documentation sections of the proposal (see Subsection V.K and Subsection V.L). Do not submit other regulatory documents (see Subsection VII.D.5, Research Involving Human Subjects/Biological Substances/Cadavers) with the proposal. The applicant should provide these documents to the USAMRMC only upon request.

O. **USAMRAA-Required Documents:** The Contract Representative at the applicant’s institution must upload the current version of the institution’s negotiated Rate Agreement, the [Certifications and Assurances for Assistance Agreements](https://cdmrp.org), and the [Representations for Assistance Agreements](https://cdmrp.org). These documents must be uploaded as separate PDF files under the Contract Representative’s “My Profile” tab of the CDMRP eReceipt system by the proposal submission deadline.

P. **Submission Date and Time:** Proposals must be approved on the CDMRP eReceipt system by the Contract Representative at the applicant’s institution by the deadline. Proposals that are incomplete or not approved electronically before the deadline will not be considered for review. The eReceipt system will *not* accept data entry, file uploads, or approvals submitted after the 5:00 p.m. Eastern time, June 20, 2006 deadline.
The timeline for the Clinical Trial Award is:

- **Online Letter of Intent:** Expected by **May 23, 2006**
- **Online Proposal Information:** Required prior to proposal submission
- **Proposal Submission/Approval Deadline:** 5:00 p.m. Eastern time, **June 20, 2006**
- **Peer Review (First Tier):** July 2006
- **Programmatic Review (Second Tier):** September 2006
- **Request for Additional Documents:** As early as 2 weeks after the completion of programmatic review
- **Notification Letter:** Approximately 4 weeks after the completion of programmatic review
- **Award Start Date:** Anticipated between December 2006 and April 2007

Q. **Electronic Submission Requirements:** Electronic submission is required. Only proposals submitted as PDF files through the CDMRP eReceipt system at [https://cdmrp.org](https://cdmrp.org) will be accepted.

Several steps are critical to successful proposal submission:

- The Proposal Information must be “Finalized for CR Approval” before the proposal is submitted. Applicants are encouraged to begin this part of the submission process early.
- Proposal Contacts must be “Finalized for CR Approval” before the proposal is submitted. The e-mail address of a Contract Representative at the applicant’s institution must be included in the Proposal Contacts. Applicants are encouraged to begin this part of the submission process early.
- Applicants are encouraged to coordinate with their Contract Representative early in the application process.
- The Contract Representative authorized to negotiate on behalf of the applicant’s institution is required to provide final approval before the proposal is accepted.
- The eReceipt system will **not** accept data entry, file uploads, or approvals submitted after the 5:00 p.m. Eastern time, June 20, 2006 deadline.
- Some items in the proposal including figures, tables, graphs, letters, or publications will need to be scanned electronically. These documents should be scanned at a resolution of 300 dpi or less.
- Applicants are encouraged to retain a date and time-stamped copy of the proposal component files as prepared by word processing software (e.g., Microsoft Word, WordPerfect) as well as the original PDF conversion file.
- The Detailed Cost Estimate form and the Budget Justification form must be uploaded under the “Required Files” tab of the CDMRP eReceipt system.
• The regulatory documents required at submission include a completed and signed Certificate of Environmental Compliance and a completed and signed Principal Investigator Safety Program Assurance form. These forms must be uploaded under the “Required Files” tab of the CDMRP eReceipt system.

VI. PROPOSAL REVIEW INFORMATION

A. Proposal Review and Selection Overview

1. Process: The CDMRP uses a two-tier review process for proposal evaluation. The two tiers differ fundamentally. The first tier is a scientific peer review of proposals against established criteria for determining scientific merit. The second tier is a programmatic review of proposals that compares submissions to each other and recommends proposals for funding based on scientific merit and overall goals of the program.

2. Peer Review: Peer review is conducted by scientific and consumer reviewers. The primary responsibility of the peer reviewers is to provide unbiased, expert advice on the scientific/technical merit and relevance of proposals based on the review criteria published for each award mechanism.

Scientific reviewers are selected for their subject matter expertise and experience with scientific peer review. Consumer reviewers are nominated by an advocacy or support organization and are selected on the basis of their leadership skills, commitment to advocacy, and interest in science. Consumers augment the peer review process by bringing the patient perspective to the assessment of science and the relevance of the research.

The peer review summary statement is a product of scientific peer review. Each summary statement includes the peer review scores and an evaluation of the project as assessed by the peer reviewers according to the evaluation criteria published in this program announcement.

3. Programmatic Review: Programmatic review is conducted by the Integration Panel, which is composed of scientists, clinicians, and consumer advocates. The scientific members of the Integration Panel represent diverse disciplines and specialty areas, and the consumer members represent national advocacy constituencies. A function of programmatic review is to structure a broad portfolio of grants across all disciplines. Programmatic review is a comparison-based process in which proposals from multiple research areas compete in a common pool. Integration Panel members base programmatic review primarily on the peer review summary statements and the proposal abstracts. The Integration Panel also may review SOWs and impact statements. Full proposals are not forwarded to programmatic review.

HBCU/MI proposals are reviewed concurrently with others in the same research area during scientific peer review. However, they may be evaluated separately during programmatic review. Consistent with the CDMRP’s goal, recommendations for funding HBCU/MI proposals are based on scientific excellence and program relevance.
B. Review Criteria

1. Peer Review: Clinical Trial Award proposals will be evaluated by peer reviewers according to the following criteria. The reviewers will evaluate:

   - Trial Design
     - Scientific rationale and preliminary data, including critical review and analysis of the literature and laboratory and preclinical evidence to support the proposed trial and its feasibility.
     - The aims, hypothesis or objectives, experimental design, methods, data collection procedures, and analyses.
     - Logistical aspects of the proposed clinical trial (e.g., communication plan, data transfer and management, and standardization of procedures among collaborating institutions).
     - Recruitment, informed consent, and screening processes.
     - Inclusion, exclusion, and randomization criteria.

   - Clinical Impact
     - The impact of the study on the treatment and/or management of prostate cancer.
     - Magnitude and scope of potential clinical applications.

   - Intervention, Drug, or Device
     - Intervention, drug, or device to be tested in the clinical trial.
     - Availability and purity of the substance to be used in the clinical trial (if applicable).
     - Documentation that an IND/IDE has been submitted (if applicable).
     - The FDA regulatory components of IND/IDE trials (if applicable).

   - Feasibility
     - Clinical feasibility of the proposed study.
     - Availability of subjects for the clinical trial, the prospect of their participation, and the likelihood of subject attrition.
     - Progress toward obtaining local IRB approval of the clinical protocol and informed consent form.

   - Statistical Plan
     - Statistical plan, including sample size projections and power analysis.
     - Consistency of data analysis plan with the study objectives.

   - Personnel
     - Whether the applicant meets the eligibility requirements.
How research team’s background and expertise are appropriate to accomplish the proposed work (i.e., statistical expertise, expertise in prostate cancer, and clinical trials).

Appropriateness of the levels of effort for successful conduct of the proposed work.

The qualifications of Medical Monitor (if applicable).

**Environment**

Evidence of an appropriate scientific environment, clinical setting, and the accessibility of institutional resources to support the study at each participating center.

Whether the research requirements are supported adequately by the accessibility to facilities and resources (including collaborative arrangements).

Institutional commitment from each participating institution.

Intellectual and material property plan that is agreed upon by all centers.

**Ethics and/or Regulatory Issues**

Ethical considerations, information privacy, and assessment of risks and benefits of participation in the clinical trial addressed.

Plan for the study investigators to complete an ethics training program and a course in the conduct of clinical research within 1 year of protocol initiation.

Plan for dealing with adverse events, which should include named agencies or offices to be notified in this event and point of contact information.

Plans for data disposition during and after the clinical trial.

Procedures for protocol modifications during the course of the study.

Plans for data and safety monitoring.

**Budget**

Whether the budget is appropriate for the proposed research.

2. **Programmatic Review:** Criteria used by the Integration Panel to make funding recommendations that maintain the PCRP’s broad portfolio include:

- Ratings and evaluations of the peer reviewers (scientific and consumer),
- Programmatic relevance,
- Relative innovation and impact,
- Program portfolio balance, and
- Adherence to the intent of the award mechanism.
Scientifically sound proposals that best fulfill the above criteria and most effectively address the unique focus and goals of the program are selected by the Integration Panel and recommended for funding to the Commanding General, USAMRMC.

VII. AWARD ADMINISTRATION INFORMATION

A. Award Notices: Each applicant will receive notification of the award status of his or her proposal. A copy of the peer review summary statement will be posted to the CDMRP eReceipt system. Applicants can expect to receive notification approximately four weeks after programmatic review.

B. Administrative Requirements: Awards are made to organizations, not individuals. An applicant must submit a proposal through, and be employed by or affiliated with, a university, college, nonprofit research institution, commercial firm, or Government agency (including military laboratories) to receive support. A prospective recipient must meet certain minimum standards pertaining to institutional support, financial resources, record of performance, integrity, organization, experience, operational controls, facilities, and conformance with safety and environmental statutes and regulations (OMB Circular A-110 and DOD Grant and Agreement Regulations) to be eligible for an award. Any organization requesting receipt of an award through this announcement must be registered in the Central Contractor Registration (CCR) database. Access to the CCR online registration is through the CCR homepage at http://www.ccr.gov.

Proposals from Federal agencies must provide a plan delineating how all funds will be obligated by September 30, 2007, and how funds will be available to cover research costs over the entire award period. The plan must include the funding mechanism(s) that will be used to carry over funds between fiscal years, such as administrative agreements with foundations, non-Federal institutions, and universities.

A change of institution is not allowed for the Clinical Trial Award.

C. Award Negotiation: For Clinical Trial Award recipients, IND approval must be received before an award can be made. If IND approval is not received by April 30, 2007, the Government reserves the right to not fund the award.

Award negotiation consists of discussions, reviews, and justifications of critical issues involving the USAMRAA. A Contract Specialist and/or representative from the USAMRAA will contact the Contract Representative authorized to negotiate contracts and grants at the applicant’s institution. Additional documentation and justifications related to the budget may be required as part of the negotiation process.

For multi-institutional studies, collaborating institutions must be willing to resolve potential intellectual and material property issues and remove institutional barriers to achieving high levels of cooperation to ensure the successful establishment and maintenance of the research project.
An intellectual and material property plan agreed to by all participating institutions may be required during award negotiations.

The award start date will be determined during the negotiation process.

D. Regulatory Review

1. Overview: Concurrent with the USAMRAA negotiation, the Office of Surety, Safety and Environment will review the Certificate of Environmental Compliance and the Principal Investigator Safety Program Assurance form submitted with the proposal. The applicable USAMRMC regulatory office will review documents related to research involving animal use, human subjects/anatomical substance use, and cadaver use submitted upon request to ensure that DOD regulations are met.

2. Certificate of Environmental Compliance: The Certificate of Environmental Compliance must be submitted with the proposal. If multiple research sites/institutions are funded in the proposal, then a Certificate of Environmental Compliance for each site will be requested at a later date.

3. Safety Program Documents: The Principal Investigator Safety Program Assurance form must be submitted with the proposal.

   A Facility Safety Plan is required; it will be requested at a later date. A Facility Safety Plan from the applicant’s institution may have been received previously and approved by the USAMRMC. A list of institutions that have approved Facility Safety Plans can be found on the USAMRMC website at https://mrmc.detrick.army.mil/crprcqsohdfsplan.asp. If the applicant’s institution is not listed on the website, contact the institution’s Facility Safety Director/Manager to initiate completion of the institution-based Facility Safety Plan. Specific requirements for the Facility Safety Plan can be found at https://mrmc.detrick.army.mil/docs/rcq/FY02FSPAppendix.doc.

   If multiple research sites/institutions are funded in the proposal, a Facility Safety Plan for each site/institution not listed in the aforementioned website will be requested at a later date.

4. Research Involving Animal Use: Not applicable for this award mechanism.

5. Research Involving Human Subjects/Biological Substances/Cadavers: In addition to local IRB approval to conduct research involving human subjects and/or human biological substances or cadavers, a second tier of IRB review and approval also is required by the DOD. This second review is conducted by the HSRRB, which is administered by the USAMRMC Office of Research Protections. The HSRRB is mandated to comply with specific laws and directives governing all research involving human subjects that is conducted or supported by the DOD. These laws and directives are rigorous and detailed and will require information in addition to that supplied to the local review board.
a. **Requirements:** Specific requirements for research involving human subjects, human biological substances, and/or cadavers can be found at [https://mrmc.detrick.army.mil/docs/rcq/HumanSubjectsAppendix.pdf](https://mrmc.detrick.army.mil/docs/rcq/HumanSubjectsAppendix.pdf).

Personnel involved in human subjects research must have appropriate instruction in the protection of human subjects. Documentation confirming that this instruction has been completed will be required during the regulatory review process.

It is expected that there will be timely resolutions of human subjects protocols submitted to the investigator’s local IRB.

Additional information pertaining to the human subjects regulatory review process, guidelines for developing protocols, and suggested language for specific issues can be found at: [https://mrmc.detrick.army.mil/rodorphrpo.asp](https://mrmc.detrick.army.mil/rodorphrpo.asp).

b. **Informed Consent Form:** An informed consent form template is located at [https://mrmc.detrick.army.mil/docs/rcq/Proconsent/ConsentFormGuidelines.doc](https://mrmc.detrick.army.mil/docs/rcq/Proconsent/ConsentFormGuidelines.doc).

c. **Intent to Benefit:** Investigators must consider the requirements of Title 10 United States Code Section 980 (10 USC 980) applicable to DOD-sponsored research before writing a research protocol. Title 10 United States Code Section 980 requires that “Funds appropriated to the Department of Defense may not be used for research involving a human being as an experimental subject unless (1) the informed consent of the subject is obtained in advance; or (2) in the case of research intended to be beneficial to the subject, the informed consent may be obtained from a legal representative of the subject.”

Furthermore and consistent with the Common Federal Policy for the Protection of Human Subjects, if an individual cannot give his or her own consent to participate in a research study, consent of the individual’s legally authorized representative must be obtained before the individual’s participation in the research. Moreover, an individual not legally competent to consent (e.g., incapacitated individuals, incompetents, minors) may not be enrolled in DOD-sponsored research unless the research is intended to benefit each subject enrolled in the study. For example, a subject may benefit directly from medical treatment or surveillance beyond the standard of care. Investigators should be aware that this law makes placebo-controlled clinical trials problematic because of the “intent to benefit” requirement whenever participation is sought of subjects from whom consent must be obtained by the legally authorized representative.

d. **Conditions Regarding DOD Funding of Research on Human Embryonic Stem Cells:** Research involving the derivation and use of human embryonic germ cells from fetal tissue may be conducted with DOD support *only* when the research is in compliance with 45 CFR 46, Subpart B; 42 USC 289g through 289g-2; US Food and Drug Administration regulations; and any other applicable Federal, state, and local laws and regulations.
Research on existing human embryonic stem (hES) cell lines may be conducted with Federal support through the DOD only if the cell lines meet the current US Federal criteria as listed on the following National Institutes of Health (NIH) website (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html). A list of the currently approved cell lines can be obtained from the NIH Human Embryonic Stem Cell Registry (http://stemcells.nih.gov/research/registry). The NIH code should be used to identify the cell lines in the proposal.

Research involving the derivation of new stem cells from human embryos or the use of hES cells not listed on the NIH Human Embryonic Stem Cell Registry may not be conducted with Federal support through the DOD.

This restriction applies to hES cells derived from blastocysts remaining after infertility treatments and donated for research, blastocysts produced from donated gametes (oocytes and sperm) for research purposes, and the products of nuclear transfer. The research is subject to all applicable local, state, and Federal regulatory requirements.

e. Clinical Trial Registry: All applicants are required to register clinical trials individually on http://www.clinicaltrials.gov/ using the Secondary Protocol ID number designation of: CDMRP-CDMRP Log Number. If several protocols exist under the same proposal, the Secondary Protocol ID number must be: CDMRP-CDMRP Log Number-A, B, C, etc. Clinical trials must be registered prior to enrollment of the first patient. All trials that meet the definition on the NIH database (see http://prsinfo.clinicaltrials.gov/, click on “Data Element Definitions,” see section 6, “Study Phase” and “Study Type”) including all Phase I-IV clinical trials and trials that do not fit into one or more phases, but that are clearly interventional or observational (e.g., some epidemiological or behavioral studies) are required to register. Address questions on registration to the http://www.clinicaltrials.gov/ administrator.

6. Award/Regulatory Approval: The applicant may not use, employ, or subcontract for the use of any human subjects, human anatomical substances/cadavers, or laboratory animals without written approval from the applicable USAMRMC regulatory office once an award is made. The applicable USAMRMC regulatory office will forward written approvals directly to the applicant.

E. Reporting Requirements: The Government requires reports to be submitted for continuation of the research and funding. The specific reports due to the Government will be described in each award instrument. (Full USAMRMC reporting requirements can be found at https://mrmc-www.army.mil, under “Links and Resources.”) Failure to submit required reports by the required date may result in a delay in or termination of award funding.

Reporting requirements include the following:

1. Research Progress Reports: Reporting requirements consist of an annual report (for each year of research except the final year) that presents a detailed summary of scientific issues and accomplishments and a final report (submitted in the last year of the award period)
that details the findings and issues for the entire project. Copies of all scientific publications and patent applications resulting from CDMRP funding should be included in the progress reports.

2. **Fiscal Reports:** Quarterly fiscal report requirements may include the Standard Form Report, SF 272, Federal Cash Transaction, used for grants and cooperative agreements to track the expenditure of funds on the research project.

3. **Non-Exempt Human Studies Reports:** For non-exempt human subjects research, documentation of local IRB continuing review (in the intervals specified by the local IRB but at least annually) and approval for continuation must be submitted directly to the Office of Research Protections – Human Research Protection Office.

4. **Animal Use Reports:** Not applicable for this award mechanism.

VIII. **OTHER INFORMATION**

A. **Disclosure of Proprietary Information outside the Government:** By submitting a proposal, the applicant understands that proprietary information may be disclosed outside the Government for the sole purpose of technical evaluation. The USAMRMC will obtain a written agreement from the evaluator that proprietary information in the proposal will only be used for evaluation purposes and will not be further disclosed or used. Funded proposals may be subject to public release under the Freedom of Information Act; proposals that are not selected for funding are not subject to public release.

B. **Government Obligation:** Applicants are cautioned that only an appointed Contracting/Grants Officer may obligate the Government to the expenditure of funds. No commitment on the part of the Government to fund preparation of a proposal or to support research should be inferred from discussions with a technical project officer. Applicants who, or organizations that, make financial or other commitments for a research effort in the absence of an actual legal obligation signed by the USAMRAA Contracting/Grants Officer do so at their own risk.

C. **Information Service:** Offerors may use the technical reference facilities of the National Technical Information Service, 5285 Port Royal Road, Springfield, Virginia 22161, for the purpose of surveying existing knowledge and avoiding needless duplication of scientific and engineering effort and the expenditure thereby represented. All other sources also should be consulted to the extent practical for the same purpose.

D. **Inquiry Review Panel:** Applicants may submit a letter of inquiry to the USAMRMC in response to funding decisions made for a given proposal. Members of the CDMRP staff, the USAMRMC Judge Advocate General staff, and USAMRAA Grants Officers constitute an Inquiry Review Panel and review each inquiry to determine whether factual or procedural errors in either peer or programmatic review have occurred, and if so, what action should be taken.
E. **Title to Inventions and Patents:** In accordance with the Bayh-Dole Act (35 USC 200 et seq.), title to inventions and patents resulting from such Federally funded research may be held by the grantee or its collaborator, but the US Government shall, at a minimum, retain nonexclusive rights for the use of such inventions. An investigator must follow the instructions in the assistance agreement concerning license agreements and patents.

F. **J-1 Visa Waiver:** It is the responsibility of the awardee to ensure that the research staff is able to complete the work without intercession by the DOD for a J-1 Visa Waiver on behalf of a foreign national in the United States under a J-1 Visa.
## IX. ACRONYM LIST

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AVI</td>
<td>Audio Video Interleave</td>
</tr>
<tr>
<td>CCR</td>
<td>Central Contractor Registration</td>
</tr>
<tr>
<td>CDMRP</td>
<td>Congressionally Directed Medical Research Programs</td>
</tr>
<tr>
<td>CFDA</td>
<td>Catalog of Federal Domestic Assistance</td>
</tr>
<tr>
<td>COI</td>
<td>Conflict of Interest</td>
</tr>
<tr>
<td>CR</td>
<td>Contract Representative</td>
</tr>
<tr>
<td>DOD</td>
<td>Department of Defense</td>
</tr>
<tr>
<td>DODGAR</td>
<td>Department of Defense Grant and Agreement Regulations</td>
</tr>
<tr>
<td>EPLS</td>
<td>Excluded Parties List System</td>
</tr>
<tr>
<td>FAR</td>
<td>Federal Acquisition Regulations</td>
</tr>
<tr>
<td>FY</td>
<td>Fiscal Year</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practices</td>
</tr>
<tr>
<td>GMP</td>
<td>Good Manufacturing Practices</td>
</tr>
<tr>
<td>HBCU/MI</td>
<td>Historically Black Colleges and Universities/Minority Institutions</td>
</tr>
<tr>
<td>hES</td>
<td>Human Embryonic Stem</td>
</tr>
<tr>
<td>HSRRB</td>
<td>Human Subjects Research Review Board</td>
</tr>
<tr>
<td>IDE</td>
<td>Investigational Device Exemption</td>
</tr>
<tr>
<td>IND</td>
<td>Investigational New Drug</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>JPEG</td>
<td>Joint Photographic Experts Group</td>
</tr>
<tr>
<td>M</td>
<td>Million</td>
</tr>
<tr>
<td>MPEG</td>
<td>Moving Picture Experts Group</td>
</tr>
<tr>
<td>NIH</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>OMB</td>
<td>Office of Management and Budget</td>
</tr>
<tr>
<td>PCRP</td>
<td>Prostate Cancer Research Program</td>
</tr>
<tr>
<td>PDF</td>
<td>Portable Document Format</td>
</tr>
<tr>
<td>PI</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>SOW</td>
<td>Statement of Work</td>
</tr>
<tr>
<td>TIFF</td>
<td>Tagged Image File Format</td>
</tr>
<tr>
<td>URL</td>
<td>Uniform Resource Locator</td>
</tr>
<tr>
<td>USAMRAA</td>
<td>US Army Medical Research Acquisition Activity</td>
</tr>
<tr>
<td>USAMRMC</td>
<td>US Army Medical Research and Materiel Command</td>
</tr>
<tr>
<td>USC</td>
<td>United States Code</td>
</tr>
<tr>
<td>WAV</td>
<td>Waveform</td>
</tr>
</tbody>
</table>